September 22, 2026 — Type 1 Diabetes TrialNet (TrialNet), the world’s leading international research network dedicated to type 1 diabetes prevention, has launched the ASCEND T1D Study.

June 1, 2026 – Type 1 Diabetes TrialNet (TrialNet), the world’s leading international research network dedicated to the prevention of type 1 diabetes (T1D), today announced the appointment of Michael Haller, MD, as Chair and Carmella Evans-Molina, MD, PhD, as Vice Chair.

June 1, 2026 – Type 1 Diabetes TrialNet (TrialNet), the world’s leading international research network dedicated to the prevention of type 1 diabetes, today announced the appointment of Michael Haller, MD, as Chair and Carmella Evans-Molina, MD, PhD, as Vice Chair.

Ayden Haselhorst, age 17, South Dakota

Ayden Haselhorst’s journey with type 1 diabetes (T1D) began a decade before his diagnosis, when he was first screened by TrialNet for autoantibodies that signal increased risk.

A new clinical study is testing rezpegaldesleukin to see if it can help people recently diagnosed with type 1 diabetes continue to make insulin by resetting the body's natural immune balance. Rezpegaldesleukin has already shown promising results in clinical trials for other autoimmune diseases, including atopic dermatitis and lupus.

After successfully giving birth to her first child in 2010, Brooke Gibson was shocked when her fertility specialist told her that she would most likely not be able to have a second biological child due to her type 1 diabetes (T1D). Confident that this information was wrong, she sought a second opinion from another fertility specialist, and together they developed a plan. 

As we begin a new year, we are excited to share TrialNet’s progress in 2025 and our plans for the year ahead.

We also want to take this opportunity to thank our participants, their families, and our research teams. Your commitment helps us learn more about how T1D progresses and contributes to advances in preventing and delaying type 1 diabetes (T1D).

When Laura Tremblay was approached by TrialNet about becoming a TrialNet Ambassador, she didn’t hesitate to say yes.

TrialNet has created a Community Advisory Board (CAB) to amplify the voices of people impacted by type 1 diabetes (T1D) in our research. As representatives of the T1D community, CAB members have the opportunity to influence TrialNet’s research, ensuring it provides the best possible experience for participants.

While conducting research in his lab at Yale University, TrialNet Chair Kevan Herold, MD, discovered an interesting outcome. Mouse models (mice genetically modified to mimic a human condition) treated with multiple antibiotics did not respond to the immune therapy teplizumab, the only FDA-approved treatment to delay the onset of type 1 diabetes (T1D).